# SHOrt Course Radiation and TASOX (TAS102 Plus Oxaliplatin) Chemotherapy in Operable Rectal Cancer

> **NCT04417699** · PHASE2 · COMPLETED · sponsor: **Providence Health & Services** · enrollment: 13 (actual)

## Conditions studied

- Rectal Cancer

## Interventions

- **DRUG:** TAS 102
- **DRUG:** Oxaliplatin

## Key facts

- **NCT ID:** NCT04417699
- **Lead sponsor:** Providence Health & Services
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-07-05
- **Primary completion:** 2023-12-14
- **Final completion:** 2024-02-21
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2025-12-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04417699

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04417699, "SHOrt Course Radiation and TASOX (TAS102 Plus Oxaliplatin) Chemotherapy in Operable Rectal Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04417699. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*